Do you want to read an article? Please log in or register.
2019 vs. 2016 ESC/EAS statin guidelines for primary prevention of atherosclerotic cardiovascular disease
Heart, Artery and Coronary DiseasesLipid-Lowering Drugs
Related content
RECOMMENDED
Lipid-Lowering Drugs
Statin Use in Primary Prevention of Atherosclerotic Cardiovascular Disease According to 5 Major Guidelines for Sensitivity, Specificity, and Number Needed to Treat
★ 3
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
JAMA Cardiol.
Mortensen MB, Nordestgaard BG
doi: 10.1001/jamacardio.2019.3665.
Cardiovascular Risk and DiseasesLipid-Lowering Drugs
Comparison of Recommended Eligibility for Primary Prevention Statin Therapy Based on the US Preventive Services Task Force Recommendations vs the ACC/AHA Guidelines
JAMA.
Pagidipati NJ, Navar AM, Mulder H, Sniderman AD, Peterson ED, Pencina MJ
doi: 10.1001/jama.2017.3416.
Cardiovascular Risk and DiseasesLipid-Lowering Drugs
LDL-Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men with Primary Elevations of LDL-Cholesterol Levels of 190 mg/dL or Above: Analyses from the WOSCOPS 5-year Randomised Trial and 20-year Observational Follow-Up
Circulation.
Vallejo-Vaz AJ, Robertson M, Catapano AL, Watts GF, Kastelein JJ, Packard CJ, Ford I, Ray KK
doi: 10.1161/
Cardiovascular Risk and DiseasesHeart, Artery and Coronary DiseasesLipid-Lowering Drugs
ACC/AHA guidelines superior to ESC/EAS guidelines for primary prevention with statins in non-diabetic Europeans: the Copenhagen General Population Study
Eur Heart J.
Mortensen MB, Nordestgaard BG, Afzal S, Falk E
doi: 10.1093/eurheartj/ehw426
RECOMMENDED
Cardiovascular Risk and DiseasesHeart, Artery and Coronary Diseases
Recommendations and Associated Levels of Evidence for Statin Use in Primary Prevention of Cardiovascular Disease: A Comparison at Population Level of the American Heart Association/American College of Cardiology/Multisociety, US Preventive Services Task Force, Department of Veterans Affairs/Department of Defense, Canadian Cardiovascular Society, and European Society of Cardiology/European Atherosclerosis Society Clinical Practice Guidelines
★ 2
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
Circ Cardiovasc Qual Outcomes
Pavlović J, Greenland P, Franco OH, Kavousi M, Ikram MK, Deckers JW, Ikram MA, Leening MJG
doi: 10.1161/CIRCOUTCOMES.120.007183
COMMENTED
Lipid-Lowering Drugs
Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants
Am Heart J.
Yebyo HG, Aschmann HE, Kaufmann M, Puhan MA
doi: 10.1016/j.ahj.2018.12.007.
Heart, Artery and Coronary Diseases
Coronary Artery Calcium for Personalized Allocation of Aspirin in Primary Prevention of Cardiovascular Disease in 2019: The Multi-Ethnic Study of Atherosclerosis (MESA)
Circulation.
Cainzos-Achirica M, Miedema MD, McEvoy JW, Al Rifai M, Greenland P, Dardari Z, Budoff M, Blumenthal RS, Yeboah J, Duprez DA, Mortensen MB, Dzaye O, Hong J, Nasir K, Blaha MJ
doi: 10.1161/CIRCULATIONAHA.119.045010.
Lipid-Lowering Drugs
Effectiveness of Interventions Aimed at Increasing Statin-Prescribing Rates in Primary Cardiovascular Disease Prevention: A Systematic Review of Randomized Clinical Trials
JAMA Cardiol.
Sparrow RT, Khan AM, Ferreira-Legere LE, Ko DT, Jackevicius CA, Goodman SG, Anderson TJ, Stacey D, Tiszovszky I, Farkouh ME, Tu JV, Udell JA
doi: 10.1001/jamacardio.2019.3066.
Lipid-Lowering Drugs
A Long-term Benefit Approach vs Standard Risk-Based Approaches for Statin Eligibility in Primary Prevention
JAMA Cardiol.
Thanassoulis G, Sniderman AD, Pencina MJ
doi: 10.1001/jamacardio.